COVID-19 pandemic challenges: on the way to overcome obstacles in realization of PAH-specific therapy treatment goals
Our observation demonstrates a case of a 40-year-old female with idiopathic pulmonary arterial hypertension World Health Organization functional class III, who was admitted to NMRC of Cardiology repeatedly due to disease progression including dyspnea worsening and exercise tolerance decrease after p...
Saved in:
| Main Authors: | E. A. Rezukhina, I. Z. Korobkova, N. M. Danilov, V. V. Gramovich, T. V. Martynyuk |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2021-11-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/6293 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01) -
The place of tadalafil in the treatment of PAH in the light of new clinical guidelines of the Eurasian Association of Cardiologists
by: T. V. Martynyuk
Published: (2024-03-01) -
Historical milestones in the study of pulmonary hypertension
by: Anna K. Osokina, et al.
Published: (2025-01-01) -
Profile of patients with portopulmonary hypertension
by: M. K. Barkovskaya, et al.
Published: (2025-06-01) -
Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01)